CN119033782B - 抗血小板药物和其用途 - Google Patents

抗血小板药物和其用途 Download PDF

Info

Publication number
CN119033782B
CN119033782B CN202410873004.4A CN202410873004A CN119033782B CN 119033782 B CN119033782 B CN 119033782B CN 202410873004 A CN202410873004 A CN 202410873004A CN 119033782 B CN119033782 B CN 119033782B
Authority
CN
China
Prior art keywords
mmol
present disclosure
compounds
alkyl
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202410873004.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN119033782A (zh
Inventor
顾自强
张袁超
何公欣
侯凯
吴豪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kejun Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Kejun Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Kejun Pharmaceutical Technology Co ltd filed Critical Shanghai Kejun Pharmaceutical Technology Co ltd
Publication of CN119033782A publication Critical patent/CN119033782A/zh
Application granted granted Critical
Publication of CN119033782B publication Critical patent/CN119033782B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN202410873004.4A 2020-07-29 2021-07-28 抗血小板药物和其用途 Active CN119033782B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/105513 2020-07-29
CN2020105513 2020-07-29
PCT/CN2021/108875 WO2022022559A1 (en) 2020-07-29 2021-07-28 Antiplatelet drugs and uses thereof
CN202180058245.8A CN116194459A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180058245.8A Division CN116194459A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途

Publications (2)

Publication Number Publication Date
CN119033782A CN119033782A (zh) 2024-11-29
CN119033782B true CN119033782B (zh) 2025-04-25

Family

ID=80037185

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202410873004.4A Active CN119033782B (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202411716601.2A Active CN119552111B (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202311275197.5A Pending CN117343000A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202180058245.8A Pending CN116194459A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202411716601.2A Active CN119552111B (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202311275197.5A Pending CN117343000A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202180058245.8A Pending CN116194459A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途

Country Status (14)

Country Link
US (2) US12410132B2 (https=)
EP (2) EP4188935A4 (https=)
JP (1) JP2023535815A (https=)
KR (2) KR102906376B1 (https=)
CN (4) CN119033782B (https=)
AR (1) AR123078A1 (https=)
AU (1) AU2021317436A1 (https=)
BR (1) BR112023001595A2 (https=)
CA (1) CA3186645A1 (https=)
ES (1) ES3046366T3 (https=)
IL (1) IL299979A (https=)
MX (1) MX2023001232A (https=)
TW (1) TW202214609A (https=)
WO (1) WO2022022559A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN116813532A (zh) * 2023-06-29 2023-09-29 上海柯君医药科技有限公司 一种哌啶化合物的制备方法
WO2025108307A1 (zh) * 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用
WO2025108300A1 (zh) * 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119176829B (zh) * 2024-11-26 2025-04-15 上海柯君医药科技有限公司 一种哌啶环化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法
CN119371453A (zh) * 2024-12-30 2025-01-28 上海柯君医药科技有限公司 一种抗血小板药物中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
US20060019929A1 (en) * 2004-07-07 2006-01-26 Albert Friesen Combination therapies employing platelet aggregation drugs
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
KR20150038369A (ko) * 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
NO2721243T3 (https=) * 2014-10-01 2018-10-20
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
EP4188935A4 (en) 2024-07-17
EP4342532B1 (en) 2025-09-03
KR20230047425A (ko) 2023-04-07
US20240279178A1 (en) 2024-08-22
MX2023001232A (es) 2023-05-15
EP4342532A2 (en) 2024-03-27
CN116194459A (zh) 2023-05-30
EP4342532C0 (en) 2025-09-03
AU2021317436A1 (en) 2023-02-23
CA3186645A1 (en) 2022-02-03
IL299979A (en) 2023-03-01
US12410132B2 (en) 2025-09-09
KR102906376B1 (ko) 2025-12-30
WO2022022559A1 (en) 2022-02-03
ES3046366T3 (en) 2025-12-01
CN117343000A (zh) 2024-01-05
EP4342532A3 (en) 2024-07-17
KR20250073569A (ko) 2025-05-27
JP2023535815A (ja) 2023-08-21
US20250333382A1 (en) 2025-10-30
CN119552111B (zh) 2026-01-02
TW202214609A (zh) 2022-04-16
CN119033782A (zh) 2024-11-29
CN119552111A (zh) 2025-03-04
BR112023001595A2 (pt) 2023-04-04
EP4188935A1 (en) 2023-06-07
AR123078A1 (es) 2022-10-26

Similar Documents

Publication Publication Date Title
CN119033782B (zh) 抗血小板药物和其用途
WO2024153119A1 (en) Kras g12d inhibitors and uses thereof
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
CN115141215B (zh) Kras g12d蛋白抑制剂和其用途
CN120882724A (zh) Kras g12d抑制剂和其用途
CN118909031B (zh) 抗冠状病毒化合物及其组合物和用途
EP4470539A1 (en) Pharmaceutical composition of antiplatelet drug, and use thereof
AU2021321905A1 (en) ATR inhibitors and uses thereof
KR102797099B1 (ko) 2-[(3r)-3-메틸모르폴린-4-일]-4-(1-메틸-1h-피라졸-5-일)-8-(1h-피라졸-5-일)-1,7-나프티리딘의 제조 방법
US11834413B2 (en) Antiplatelet drugs and uses thereof
RU2841656C1 (ru) Антитромбоцитарные лекарственные средства и их применение
HK40117914A (zh) 抗血小板药物和其用途
HK40117914B (zh) 抗血小板药物和其用途
HK40090099A (zh) 抗血小板药物和其用途
JPH0412273B2 (https=)
WO2023138621A1 (en) Atr inhibitors and uses thereof
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40117914

Country of ref document: HK